222 results about "Inflammatory cell infiltration" patented technology

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention provides a compound probiotic for relieving acute lung injury and application of the compound probiotic, and particularly discloses application of the compound probiotic consisting of bifidobacterium animalis YRK-12 and lactobacillus rhamnosus LRa-Y8 in preparation of a medicine for relieving the acute lung injury. Wherein the preservation number of the bifidobacterium animalis YRK-12 is CGMCC (China General Microbiological Culture Collection Center) No.28597; the preservation number of the lactobacillus rhamnosus LRa-Y8 is CGMCC (China General Microbiological Culture Collection Center) No. 34186. Experimental verification shows that the compound probiotics can remarkably relieve acute lung injury induced by lipopolysaccharide (LPS) through a synergistic effect; specifically, the weight loss rate of mice is reduced, pathological injuries of lung tissues are improved (the structural integrity of alveolar alveoli is maintained, and inflammatory cell infiltration is reduced), the levels of proinflammatory factors (IL-1beta, TNF-alpha and IL-6) in serum and lung tissues are reduced, and the level of anti-inflammatory factors (IL-4) is increased, so that the immune balance of the lung is regulated through an intestine-lung axis; and a safe and effective novel micro-ecological regulation strategy is provided for prevention and treatment of acute lung injury.

The invention belongs to the technical field of medicines, and discloses application of baicalein in drugs related to the treatment effect of S protein and LPS induced acute lung injury. Specifically, the invention discloses an application of baicalein in preparation of drugs playing a protective role in treating pulmonary edema, inflammatory cell infiltration and cytokine storm caused by acute lung injury induced by S protein combined with LPS. Pharmacological experiments prove that baicalein has an anti-inflammatory effect in treatment of acute lung injury induced by S protein combined with LPS, and can improve pulmonary edema and promote lesion lung tissue repair.

The invention discloses a five-membered heterocyclic compound as well as a preparation method, an intermediate, a composition and application thereof. Specifically provided is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound provided by the invention has excellent biological activity; on one hand, free radicals can be removed, so that activation of tyrosinase is reduced; on the other hand, the activity of activated tyrosinase can be inhibited, and generation of melanin is reduced from multiple aspects; besides, the compound can reduce skin pigmentation induced by ultraviolet (UVB), has no obvious stimulation and inflammatory cell infiltration during administration, is safe and good in tolerance, has better solubility and preparation performance, is good in skin feeling, and is expected to be widely applied in the industries of medicine, cosmetics and beauty. # imgabs0 #

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The present application relates to; a pharmaceutical composition, a food composition and a feed composition for preventing or treating fatty liver diseases; and a method for treating fatty liver diseases by using same, the pharmaceutical composition comprising a Bifidobacterium pseudolongum strain deposited under accession number KCTC 15133BP, a culture of the strain, a lysate of the strain, an extract of the strain, or a mixture thereof. The Bifidobacterium pseudolongum strain deposited under accession number KCTC 15133BP, a culture of the strain, a lysate of the strain, an extract of the strain, or a mixture thereof, according to the present invention, alleviates inflammatory cell infiltration and fibrosis in the liver, and exhibits the effects of inhibiting cholesterol synthesis and inhibiting triglyceride accumulation in the liver, and thus can be used for treating fatty liver diseases, particularly nonalcoholic fatty liver disease.

The invention provides a traditional Chinese medicine monomer composition for preventing and / or treating pulmonary fibrosis as well as a preparation and application thereof, and belongs to the technical field of biological medicines. The traditional Chinese medicine monomer composition comprises the following components: schisandrin B and platycodin D. The traditional Chinese medicine monomer composition can obviously reduce fiber cell and collagen deposition, relieve inflammatory cell infiltration, obviously reduce the lung coefficient, alveolar inflammation score and pulmonary fibrosis score, and recover the normal physiological structure of rat lung tissue. The traditional Chinese medicine monomer composition provided by the invention can reduce the expression contents of KL-6, MMP-7, SP-A and SP-D and lung tissue HYP in serum, and has the effects of relieving collagen deposition and alveolar epithelium injury, maintaining alveolar homeostasis and improving pulmonary fibrosis. Therefore, the traditional Chinese medicine composition provided by the invention is definite and reliable in curative effect and can be used for preparing medicines for preventing and / or treating pulmonary fibrosis.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can reduce the levels of MDA and NO in serum of mice and improve the activity of SOD and CAT and the content of GSH so as to relieve oxidative stress injury; inflammatory cell infiltration of nasal mucosa is reduced, and lung tissue inflammatory mediator level and inflammation-related gene expression are reduced to inhibit inflammation; th1 / Th2 immune balance is regulated, Th2 type cytokines are reduced, Th1 type cytokines are increased, and the high-dosage effect is close to that of loratadine. The strain has a treatment effect on allergic rhinitis through multiple mechanisms, and a new choice is provided for treatment of the strain.

The invention discloses a lactobacillus paracasei strain with an effect of relieving inflammatory bowel diseases and application thereof, and belongs to the technical field of microbial fermentation. The strain is Lactobacillus paracasei JGSLP08, and the preservation number of the Lactobacillus paracasei JGSLP08 is CGMCC (China General Microbiological Culture Collection Center) NO.34274. The invention further discloses a preparation method of the Lactobacillus paracasei JGSLP08. The strain has the characteristics of strong acid resistance, bile salt resistance and gastrointestinal fluid resistance, can effectively inhibit salmonella typhimurium, escherichia coli and staphylococcus aureus, and has an excellent antioxidant effect. A DSS-induced colitis mouse model shows that the lactobacillus paracasei can effectively improve the DIA score of a mouse, regulate inflammatory factors, reduce oxidative stress injury, relieve inflammatory cell infiltration and protect the integrity of mucosal epithelium, so that the inflammatory bowel disease is relieved and / or treated.

The invention belongs to the field of biological medicines, and discloses application of flufenidone in preparation of a medicine for treating pancreatic diseases. Researches find that the flufenidone can improve serum amylase and lipase levels of an acute pancreatitis model mouse, and can improve pancreatic tissue edema, necrosis and inflammatory cell infiltration of the acute pancreatitis model mouse; the traditional Chinese medicine composition can improve acute pancreatitis model mouse lung tissue alveolar interval thickening and inflammatory cell infiltration, and provides guarantee for application of the traditional Chinese medicine composition in preparation of drugs for treating pancreatic diseases.

The invention discloses a lindera glauca extract, a preparation method thereof and application of the lindera glauca extract in preparation of drugs for preventing and / or treating rheumatoid arthritis. The research finds that the lindera glauca extract can obviously reverse arthritic rat plantar part swelling and toe bending, relieve ankle joint injury, relieve synovial hyperplasia and inflammatory cell infiltration, inhibit joint fusion, relieve joint gap stenosis, relieve articular surface fusion tendency, increase bone mineral density and bone trabecula number, reduce bone trabecula separation degree and improve joint fusion. The lindera glauca extract can be used for relieving rheumatoid arthritis by protecting the inherent structure of joint tissues and improving inflammation, so that a novel natural medicine choice is provided for preventing and / or treating rheumatoid arthritis.

The invention discloses a medicine composition for treating atopic dermatitis, a preparation method and application, the medicine composition comprises inactivated malassezia sphaeroides, and the strain preservation number of the malassezia sphaeroides is ATCC 96807. The cream composition disclosed by the invention is externally applied to local treatment of skin lesions of specific dermatitis, supplements skin symbiotic bacteria, assists in recovering skin barriers of patients, remarkably inhibits growth and proliferation of staphylococcus aureus at the skin lesions of dermatitis and exocrine toxins, remarkably relieves inflammatory response, reduces the thickness of cuticles and reduces inflammatory cell infiltration; the traditional Chinese medicine composition assists the treatment of atopic dermatitis through the effects of the proinflammatory factors and the expression and secretion of the proinflammatory factors, has a remarkable treatment effect on the atopic dermatitis, is quick to take effect, small in toxic and side effects and good in safety, and has a good medicinal prospect.

The invention discloses application of a TIMM10 gene as a target spot in resisting influenza A virus, and belongs to the technical field of biological medicine. Specifically, TIMM10 gene knock-down is carried out on A549 cells, and it is found that in the cells with knocked-down TIMM10, expression of main protein hemagglutinin and nucleoprotein of influenza viruses is remarkably improved, and virus RNA and virus titer in supernate are also remarkably increased; overexpression of TIMM10 in A549 cells inhibits replication and infectivity of IAV in the cells. A further in-vivo experiment is carried out through a TIMM10 whole body knockout heterozygote mouse, and a result shows that the lung of the TIMM10 heterozygote mouse shows more serious pulmonary infection, including pulmonary hemorrhage and increased inflammatory cell infiltration. Based on the effect of TIMM10 in the influenza virus infection process, the invention provides a new therapeutic target, and provides a new thought and direction for developing a therapeutic strategy for IAV in the future.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The invention belongs to the technical field of skin disease treatment and medicine, and particularly relates to an external pharmaceutical composition for treating atopic dermatitis and a preparation method and application thereof. The medicine composition is liquid medicine composed of blumea balsamifera oil, perfoliote knotweed herb and piper cubeba extract and is specially used for treating the atopic dermatitis (AD). According to the composition, the blumea balsamifera oil is innovatively used as a main component and cooperates with the perfoliote knotweed herb and the piper cubeba extract to form an efficient treatment scheme, and the curative effect of the composition is remarkably superior to that of a traditional method for singly using the blumea balsamifera oil. Experiments prove that the composition can effectively improve the skin barrier function, regulate immune disorder, reduce the levels of serum IgE and TSLP and inflammatory factors IL-4 and IFN-gamma, and reduce inflammatory cell infiltration, so that the AD symptom is relieved, and the recurrence rate is reduced.

The invention provides a novel medicine for treating psoriasis by recovering keratinocyte Pp6 and application of the novel medicine. The novel medicine has the structural formula shown in the formula (I), has the remarkable effects of inhibiting epidermal hyperplasia, reducing the infiltration number of dermal inflammatory cells and the like on a psoriasis focus area, and has the very excellent relieving or treating effect on psoriasis.

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

The invention discloses an intestinal microneedle anastomosis stent with an antibacterial function and a preparation method and application thereof, which can effectively and physically isolate an anastomotic stoma from intestinal contents and provide a relatively clean local environment for healing of the anastomotic stoma. The microneedle anastomotic stent is fixed at the anastomotic stoma, so that the tension at the anastomotic stoma can be further reduced, and the occurrence of anastomotic stoma leakage caused by overlarge tension is avoided; the microneedle layer on the surface of the stent can realize in-situ long-acting slow release of berberine hydrochloride (BBH) on the superficial layer of an anastomotic stoma, so that the drug utilization rate of the BBH is improved, the initial inflammation of the anastomotic stoma can be effectively reduced, and the anastomotic stoma can be regulated and controlled to be better healed. Animal experiment results prove that the implantation of the microneedle anastomosis stent can effectively reduce inflammatory cell infiltration of local tissues, reduce anastomotic stoma arrangement and regulate the anastomotic stoma to heal smoothly.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The invention discloses an application of isothunberine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating asthma diseases. It is found that in an OVA-induced mouse asthma model, the isothunberine significantly reduces airway resistance excited by acetylcholine, improves inflammatory cell infiltration and airway mucus high secretion of asthma model mouse lung tissue, reduces the levels of lgE and OVA-lgE in serum and related inflammatory factors in alveolar lavage fluid, and has the effect of preventing and treating asthma. Therefore, the effect of treating asthma is achieved. Therefore, the isothunberine has the potential of preventing or treating the asthma, provides a new treatment mode for the treatment of the asthma, and has a wide application prospect.

The invention discloses a traditional Chinese medicine composition for treating allergic asthma and a preparation method thereof, and the traditional Chinese medicine composition comprises the following components in parts by weight: 2-10 parts of honey-fried ephedra, 3-10 parts of scutellaria baicalensis, 9-15 parts of momordica grosvenori, 9-15 parts of rhizoma dioscoreae nipponicae, 5-10 parts of scalded semen armeniacae amarae, 2-10 parts of liquorice, 3-10 parts of fried fructus perillae, 3-9 parts of fried semen brassicae, 5-10 parts of schizonepeta, 3-10 parts of platycodon grandiflorum and 5-12 parts of fried semen raphani. The pharmaceutical composition disclosed by the invention is a pure traditional Chinese medicine preparation, and can be used for reducing the level of eosinophilic granulocytes, increasing the number of alveolar macrophages and effectively improving abnormal immune response in an asthma process; lesion degrees such as lung tissue inflammatory cell infiltration, alveolar wall edema and goblet cell hyperplasia are relieved; secretion of Th2 type inflammatory cell related factors and IgE is reduced, and finally the effect of treating allergic asthma inflammatory response is achieved.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The invention discloses application of KLF14 agonist perhexiline in preparation of a medicine for treating acute lung injury, and belongs to the technical field of biological medicine. The high expression of the KLF14 in the acute lung injury model lung is systematically clarified. KLF14 is inhibited by adopting adenovirus knock-down, and it is found that KLF14 deletion can aggravate acute lung injury induced by lipopolysaccharide by mediating release of neutrophil NETosis and inflammatory factors. The activation of the perhexiline on the KLF14 can effectively inhibit the release of neutrophil NETosis and inflammatory factors, so that the lung morphological change caused by lipopolysaccharide can be inhibited in vivo, the lung interstitial inflammatory cell infiltration is weakened, and the effect of relieving the acute lung injury is achieved. The invention provides an application of perhexiline as a KLF14 agonist in relieving acute lung injury, and provides a new therapeutic target and therapeutic drug for prevention and treatment of acute lung injury.

The invention discloses application of guaiacol in treatment of rheumatoid arthritis, and particularly relates to application of guaiacol in preparation of drugs for treating rheumatoid arthritis. Cell experiments prove that guaiacol can effectively down-regulate expression of proinflammatory factors in macrophages and up-regulate expression of anti-inflammatory factors, and has remarkable anti-inflammatory activity; animal experiments show that the guaiacol effectively relieves rheumatoid arthritis model mouse diseases, and the specific manifestation is that the guaiacol obviously relieves the mouse claw swelling degree, reduces the arthritis disease score, obviously improves joint inflammatory cell infiltration, repairs cartilage injury, inhibits osteoclast generation and reduces the number of joint apoptotic cells; meanwhile, the level of proinflammatory factors in serum of mice can be effectively reduced, and the level of proinflammatory repair factors can be up-regulated. The invention proves that guaiacol has a definite curative effect on rheumatoid arthritis, good biological safety and no obvious side effect, provides a new effective active component for the treatment of rheumatoid arthritis, and has a good prospect of being developed into the medicine for treating rheumatoid arthritis.

The application discloses application of a heteroterpene compound I in preparation of a heart failure resisting drug. The heteroterpene compound I is obtained by separation and purification from a marine fungus Aspergillus terreus GZU-311, and is used to treat a mouse heart failure model induced by adriamycin or left anterior descending coronary artery ligation, and it is found that the heteroterpene compound I can improve the heart function of the mouse, reduce myocardial cell damage, inhibit myocardial connective tissue thickening, improve myocardial cell arrangement disorder, reduce inflammatory cell infiltration, and has an effect of resisting heart failure. Therefore, the application provides application of the heteroterpene compound I in preparation of a heart failure resisting drug. The application enriches drug source molecules that can be used for treating heart failure, and is helpful to development of an anti-heart failure drug and clinical treatment.

The application provides application of a Baoji oral liquid composition in preparation of a functional dyspepsia medicine, and relates to the technical field of medicines. The application is based on the Baoji oral liquid, and it is found that the Baoji oral liquid has a remarkable effect on treating functional dyspepsia, especially cisplatin-induced functional dyspepsia. Specifically, the Baoji oral liquid can rapidly restore body weight, significantly improve body weight gain, steadily promote food intake, significantly improve gastric emptying rate and intestinal propulsion rate, protect the gastric mucosa layer, reduce inflammatory cell infiltration, repair the mucosa layer and muscle layer, improve the expression of serum gastrin and motilin, and improve the expression level of IL-4 in the gastric tissue and reduce the expression level of IL-1beta. The Baoji oral liquid has remarkable efficacy when applied in preparation of a functional dyspepsia medicine.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

The application discloses application of a PRMT3 inhibitor SGC707 in preparation of a drug for treating pulmonary fibrosis, and for the first time verifies that a selective PRMT3 inhibitor SGC707 can dose-dependently inhibit expression of fibrosis markers such as COL1A1 and alpha-SMA in fibroblasts induced by TGF-beta 1 in vitro; in a bleomycin (BLM) induced mouse pulmonary fibrosis model, SGC707 administration can significantly improve lung tissue collagen deposition, reduce inflammatory cell infiltration, repair alveolar structure damage, and effectively down-regulate expression levels of fibrosis related proteins in lung tissues. It is proved that PRMT3 is a functional target with important intervention value in pulmonary fibrosis, SGC707 has definite anti-pulmonary fibrosis activity in vitro and in vivo, and a new drug strategy is provided for treatment of pulmonary fibrosis.

The application discloses a kind of treatment granulomatous lobular mastitis plaster and preparation method thereof, it is related to traditional Chinese medicine technical field, and its technical solution points are: rhubarb, golden poplar, radix scutellariae, sanguisorba officinalis, gardenia, turmeric, purple grass, water decoct 2 times, first time 9-11 times water amount of medicinal materials is added, decoct 1-3 hours, second time 6-9 times water amount of medicinal materials is added, decoct 1-2 hours, two water decocting liquids are combined, after filtration, concentrate and obtain ointment, carry out coating, cut according to specification and place to make it solidification and shape.The application can realize the treatment granulomatous lobular mastitis, can reduce mastitis inflammation index score and inflammatory cell infiltration degree, by reducing the expression of IL6, CD86, TYROBP, ITGAX and regulating related path, play the role of treatment granulomatous lobular mastitis.